首页> 外文期刊>BMC Public Health >High variability of TB, HIV, hepatitis C treatment and opioid substitution therapy among prisoners in Germany
【24h】

High variability of TB, HIV, hepatitis C treatment and opioid substitution therapy among prisoners in Germany

机译:德国囚犯结核病,艾滋病毒,丙型肝炎治疗和阿片类药物替代疗法的高变异性

获取原文
           

摘要

In Germany, medical care of prisoners is completely separated from extramural health care. The extent and quality of medical care among prisoners in Germany are therefore largely unknown. We performed a secondary data analysis of pharmacy sales data for tuberculosis (TB), HIV, hepatitis C (HCV) and opioid substitution treatment (OST) delivered to prisons in 11 federal states (FS) in Germany between 01/2012 and 03/2013. The aims of this study were to assess (i) the treatment availability for the selected diseases and OST in German prisons, (ii) the proportion of prisoners treated per FS and overall for TB, HIV, HCV and OST during the study period. Substances unique to or typically used for the treatment of each disease were defined as marker substances with defined daily doses (DDD). For each marker substance we assessed the cumulative number of DDD, the average daily number of DDD (DDDd) and average treatment prevalence per day in percent (adTP). Accordingly, the DDDd represents one person treated per day and the adTP means the proportion of prisoners treated per day. We compared the adTP of the diseases with previously measured prevalences. We obtained data from pharmacies supplying prisons in 11 of 16 German FS. Of the included prisons, 41% were supplied with medicines for TB, 71% for HIV and 58% for HCV and OST. Twice as many delivered marker substances for TB were indicated for the continuation phase and chemoprevention than the intensive phase. The HIV adTP ranged from 0.06% to 0.94%, HCV adTP ranged from 0.03% to 0.59% and OST adTP ranged from 0% to 7.90%. The overall adTP for the respective treatment was 0.39% for HIV, 0.12% for HCV and 2.18% for OST. According to our findings treatment rates for TB were consistent with the expected TB prevalence, at least in Berlin. HIV treatment seems to be offered to an adequate proportion of estimated infected prisoners. In contrast, the HCV treatment prevalence was low. High variation among FS in provision of all treatments, particularly of OST, point to inconsistent treatment practices, although nationwide extramural treatment guidelines for Germany exist.
机译:在德国,囚犯的医疗与壁外医疗完全分开。因此,在德国囚犯中医疗保健的程度和质量在很大程度上是未知的。我们对01/2012年至03/2013年之间送往德国11个联邦州(FS)监狱的结核病(TB),HIV,丙型肝炎(HCV)和阿片类药物替代治疗(OST)的药房销售数据进行了二次数据分析。这项研究的目的是评估(i)在德国监狱中针对特定疾病和OST的治疗可用性,(ii)在研究期间,每个FS以及结核病,HIV,HCV和OST总体治疗的囚犯比例。每种疾病特有的或通常用于治疗每种疾病的物质被定义为具有确定的每日剂量(DDD)的标记物质。对于每种标记物,我们评估了DDD的累计数量,DDD的平均每日数量(DDDd)和每天的平均治疗患病率(百分比)(adTP)。因此,DDDd代表每天接受治疗的一个人,adTP表示每天接受治疗的囚犯比例。我们将疾病的adTP与先前测得的患病率进行了比较。我们从16个德国FS中有11个监狱的药房获得了数据。在其中包括的监狱中,有41%为结核病提供了药品,为HIV提供了71%,为HCV和OST提供了58%。与强化阶段相比,在延续阶段和化学预防阶段,指示出的结核病标记物质的数量是其两倍。 HIV adTP的范围为0.06%至0.94%,HCV adTP的范围为0.03%至0.59%,而OST adTP的范围为0%至7.90%。相应治疗的总体adTP为:HIV为0.39%,HCV为0.12%,OST为2.18%。根据我们的发现,至少在柏林,结核病的治疗率与预期的结核病患病率一致。似乎有足够比例的估计被感染囚犯接受了艾滋病毒治疗。相反,HCV治疗的患病率较低。尽管在德国有全国范围的壁外治疗指南,但在所有治疗方法,特别是OST治疗方面,FS差异很大,这表明治疗方法不一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号